Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants-Reference-Cited by-同舟云学术

Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants

Published:2017 Issue:7 Volume:40 Page:1078-1085
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Mukai Yuji¹,Narita Masayuki¹,Akiyama Erika¹,Ohashi Kanami¹,Horiuchi Yasutaka¹,Kato Yuka¹,Toda Takaki¹,Rane Anders²,Inotsume Nobuo¹

Affiliation:

1. Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy

2. Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/40/7/40_b17-00150/_pdf

Reference43 articles.

1. 1) Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet., 40, 263–281 (2001).

2. 2) Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am. J. Transplant., 12, 1975–1982 (2012).

3. 3) Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos., 27, 410–416 (1999).

4. 4) Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin. Pharmacol. Toxicol., 105, 327–332 (2009).

5. 5) Hirota T, Ieiri I. Drug–drug interactions that interfere with statin metabolism. Expert Opin. Drug Metab. Toxicol., 11, 1435–1447 (2015).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome <i>P450 2C9*3</i> as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database;Biological and Pharmaceutical Bulletin;2024-03-15

2. Genetic Determinants of Response to Statins in Cardiovascular Diseases;Current Cardiology Reviews;2024-03

3. Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru;Pharmacia;2023-08-15

4. Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review;Plants;2023-01-31

5. Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana;Biomédica;2019-09-01